Herpes Zoster (Shingles) - Pipeline Review, H1 2018

  • ID: 4479906
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • Vaccitech Ltd
  • XBiotech Inc
  • MORE
Herpes Zoster (Shingles) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2018, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1 and 1 respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • Vaccitech Ltd
  • XBiotech Inc
  • MORE
Introduction

Report Coverage

Herpes Zoster (Shingles) - Overview

Herpes Zoster (Shingles) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Herpes Zoster (Shingles) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

GeneOne Life Science Inc

GlaxoSmithKline Plc

NAL Pharmaceuticals Ltd

NanoViricides Inc

Vaccitech Ltd

XBiotech Inc

Herpes Zoster (Shingles) - Drug Profiles

GLS-5100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Shingles - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Shingles - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varicella zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpes Zoster (Shingles) - Dormant Projects

Herpes Zoster (Shingles) - Discontinued Products

Herpes Zoster (Shingles) - Product Development Milestones

Featured News & Press Releases

Jan 26, 2018 : GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over

Dec 06, 2017: Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates

Dec 06, 2017: New data supports the safety and efficacy of GSK’s Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients

Nov 20, 2017: New Shingles Vaccine: CUMC Experts Discuss what it Means for Patients

Oct 26, 2017: Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center

Oct 25, 2017: CDC’s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up

Oct 25, 2017: Shingrix with QS-21 Stimulon Receives Positive Recommendation from CDCs Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles

Oct 23, 2017: Shingrix approved in the US for prevention of shingles in adults aged 50 and over

Oct 20, 2017: FDA Approves GSK's Shingles Vaccine with Agenus QS-21 Stimulon Adjuvant

Oct 13, 2017: GSK announces first approval of Shingrix in Canada

Oct 13, 2017: GSK's Shingrix Containing Agenus' QS-21 Stimulon Adjuvant Receives Marketing Authorization from Health Canada

Sep 13, 2017: FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over

Sep 13, 2017: GSK's Shingrix Containing Agenus' QS-21 Stimulon Adjuvant Receives Unanimous FDA Advisory Committee Recommendation for Approval

Jul 10, 2017: NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin

Jun 26, 2017: NanoViricides Poster Novel Nanoviricides Highly Effective Against Varicella Zoster Virus in Cell Culture to be Presented Today at the 2017 Annual Meeting of American Society of Virology

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Herpes Zoster (Shingles), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2018

Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2018

Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2018

Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2018

Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H1 2018

Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2018

Herpes Zoster (Shingles) - Dormant Projects, H1 2018

Herpes Zoster (Shingles) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Herpes Zoster (Shingles), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • Vaccitech Ltd
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll